RVU — Ryvu Therapeutics SA Cashflow Statement
0.000.00%
Last trade - 00:00- PLN506.32m
- PLN494.55m
- PLN62.25m
Annual cashflow statement for Ryvu Therapeutics SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -79.1 | -83.8 | -92.1 | -111 | -101 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 22.5 | 31.4 | 10.9 | -7.96 | 19.1 |
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -9.22 | 61.2 | -14.3 | -20.6 | -41.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -58.9 | 21.3 | -84.5 | -129 | -114 |
| Capital Expenditures | -12 | -9.29 | -201 | -5.9 | -7.47 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 20 | 9.98 | 5.65 | 143 | 24.6 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 8.05 | 0.69 | -196 | 137 | 17.2 |
| Financing Cash Flow Items | 0.821 | 0.057 | 250 | -0.006 | 0.001 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -2.15 | -2.46 | 241 | 94.2 | -3.05 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -53 | 18.7 | -44 | 102 | -100 |